Bio Regenmed
A national high-tech leader creating and manufacturing innovative biomedical materials for advancing human tissue engineering and organ repair.
A national high-tech leader creating and manufacturing innovative biomedical materials for advancing human tissue engineering and organ repair.
Bio Regenmed is a national high-tech leader in the biopharma and biotechnology industries. The company focuses on creating and manufacturing innovative biomedical materials to advance human tissue engineering and organ repair. The most recent investment, a Series C round, took place on 28 December 2023. The investors in this round included Shaanxi Investment Capital, Xi'an Caijin, Chang An Hui Tong Fund, and Yuhua Capital. With its innovative approach and strong investor backing, Bio Regenmed is poised to make significant strides in the biomedicine sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | Unknown | 4 |
|
28 Dec 2023 |
No recent news or press coverage available for Bio Regenmed.
We care about your data, and we'd love to use cookies make your experience better.